NCT07246005

LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus

A Randomised Pilot Study Assessing the Optimal Duration of Anticoagulation for Left Ventricular Thrombus

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 120 (estimated)
• Sponsor: Queen Mary University of London · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The LVT DURATION (Optimal Duration of Anticoagulation for LV Thrombus) is a pilot study planned to assess the practicalities of conducting a randomised control trial (RCT) whilst establishing data around the ideal duration of anticoagulation in the treatment of LV thrombus. The main objectives of the study are: * To assess the practicalities of conducting an RCT with regard to recruitment, retention, and outcome measurement. * To identify the optimal length of anticoagulation in the treatment of LV Thrombus After randomisation participants will: * Continue their prescribed oral anticoagulant for the remainder of the trial * Discontinue their prescribed oral anticoagulant for the remainder of the trial

Conditions

• Left Ventricular Thrombus

Interventions

Type	Name	Description
DRUG	Continue rivaroxaban or apixaban or warfarin	The study is asessing the impact of discontinuation of oral anticoagulation in patients with LV thrombus diagnosis.
DRUG	Discontinue rivaroxaban or apixaban or warfarin	discontinue rivaroxaban or apixaban or warfarin

Timeline

• Start date: 2026-12-01
• Primary completion: 2027-12-01
• Completion: 2027-12-01
• First posted: 2025-11-24
• Last updated: 2026-02-27

Locations

1 site across 1 country: United Kingdom

Regulatory

• FDA-regulated drug study